Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
13 January 2024 - 8:15AM
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a
global leader in innovations for active healing, announced today
the issuance on January 11, 2024 of previously disclosed inducement
equity awards to Robert (Rob) Claypoole in connection with this
appointment as President and Chief Executive Officer, and Principle
Executive Officer of the Company.
The awards consist of 375,000 restricted share units and options
to purchase 850,000 shares of the Company’s Class A common stock.
Both awards will vest in four equal installments on the first four
anniversaries of January 10, 2024, subject to Mr. Claypoole’s
continued employment with the Company through each applicable
vesting date. The exercise price for the options is $4.89.
The awards were approved in accordance with Nasdaq Listing Rule
5635(c)(4).
About BioventusBioventus delivers clinically
proven, cost-effective products that help people heal quickly and
safely. Its mission is to make a difference by helping patients
resume and enjoy active lives. The Innovations for Active Healing
from Bioventus include offerings for Pain Treatments, Restorative
Therapies and Surgical Solutions. Built on a commitment to high
quality standards, evidence-based medicine and strong ethical
behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.bioventus.com and follow the
Company on LinkedIn and Twitter. Bioventus and the Bioventus logo
are registered trademarks of Bioventus LLC.
Investor and Media Inquiries:Dave
Crawford919-474-6787Dave.Crawford@bioventus.com
Bioventus (NASDAQ:BVS)
Historical Stock Chart
From Apr 2024 to May 2024
Bioventus (NASDAQ:BVS)
Historical Stock Chart
From May 2023 to May 2024